Introduction: Bile duct complications are common after liver transplantation. The impact of preservation solution is unclear. Aim: We investigated the impact of different preservation solutions with and without diluted bile on a human biliary tract carcinoma cell line. Methods: The human biliary tree carcinoma cell line SK-ChA-1 was cultured with either medium or University of Wisconsin solution (UW), histidine-tryptophane-ketoglutarate (HTK) solution, Celsior or physiological saline for 6h, 10h or 12h at 6℃- 8℃ and metabolic activity was measured by a MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)-test immediately, after 12h or 24h. Cells were also incubated in combination with diluted porcine bile. Results: Immediately after cold storage of 6h HTK and UW decreased metabolic activity whereas Celsior increased metabolic activity after 10h or 12h of cold ischemia. After 12h or 24h no major differences were found any more. Incubation with bile in combination with HTK, Celsior or NaCl decreased metabolic activity, whereas UW abolished this effect. Conclusion: On a cellular level differences between preservation solutions were found, especially in combination with bile. Further studies are warranted to determine whether this results in clinically significant differences in biliary complications.
References
[1]
S. A. Alqahtani, “Update in Liver Transplantation,” Current Opinion in Gastroenterology, Vol. 28, No. 3, 2012, pp. 230-238. doi:10.1097/MOG.0b013e3283527f16
[2]
O. Abbasoglu, “Liver Transplantation: Yesterday, Today and Tomorrow,” World Journal of Gastroenterology, Vol. 14, No. 20, 2008, pp. 3117-3122.
doi:10.3748/wjg.14.3117
[3]
G. A. Bishop, F. L. Ierino, A. F. Sharland, et al., “Approaching the Promise of Operational Tolerance in Clini- cal Transplantation,” Transplantation, Vol. 91, No. 10, 2011, pp. 1065-1074. doi:10.1097/TP.0b013e318215e742
[4]
A. A. Schnitzbauer, H. J. Schlitt and E. K. Geissler, “Influence of Immunosuppressive Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Gap between Basic Science and Clinical Evidence,” Transplantation, Vol. 91, No. 11, 2011, pp. 1173-1176.
doi:10.1097/TP.0b013e318215e72b
[5]
F. Aberg, H. Isoniemi and K. Hockerstedt, “Long-Term Results of Liver Transplantation,” Scandinavian Journal of Surgery: SJS: Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society, Vol. 100, No. 1, 2011, pp. 14-21.
[6]
D. G. Buck and A. B. Zajko, “Biliary Complications after Orthotopic Liver Transplantation,” Techniques in Vascu- lar and Interventional Radiology, Vol. 11, No. 1, 2008, pp. 51-59. doi:10.1053/j.tvir.2008.05.006
[7]
S. C. Chan and S. T. Fan, “Biliary Complications in Liver Transplantation,” Hepatology International, Vol. 2, No. 4, 2008, pp. 399-404. doi:10.1007/s12072-008-9092-z
[8]
T. Hampe, A. Dogan, J. Encke, et al., “Biliary Complications after Liver Transplantation,” Clinical Transplantation, Vol. 20, No. 17, 2006, pp. 93-96.
[9]
B. Y. Tung and M. B. Kimmey, “Biliary Complications of Orthotopic Liver Transplantation,” Digestive Diseases, Vol. 17, No. 3, 1999, pp. 133-144.
doi:10.1159/000016918
[10]
F. Rayya, J. Harms, A. P. Martin, et al., “Comparison of Histidine-Tryptophan-Ketoglutarate Solution and University of Wisconsin Solution in Adult Liver Transplantation,” Transplantation Proceedings, Vol. 40, No. 4, 2008, pp. 891-894. doi:10.1016/j.transproceed.2008.03.044
[11]
F. A. Garcia-Gil, J. Arenas, A. Guemes, et al., “Preserva- tion of the Liver Graft with Celsior Solution,” Transplantation Proceedings, Vol. 38, No. 8, 2006, pp. 2385-2388.
doi:10.1016/j.transproceed.2006.08.032
[12]
F. A. Garcia-Gil, M. T. Serrano, L. Fuentes-Broto, et al., “Celsior versus University of Wisconsin Preserving Solutions for Liver Transplantation: Postreperfusion Syndrome and Outcome of a 5-Year Prospective Randomized Controlled Study,” World Journal of Surgery, Vol. 35, No. 7, 2011, pp. 1598-1607.
doi:10.1007/s00268-011-1078-7
[13]
H. Janssen, P. H. Janssen and C. E. Broelsch, “UW Is Superior to Celsior and HTK in the Protection of Human Liver Endothelial Cells against Preservation Injury,” Liver Transplantation, Vol. 10, 2004, pp. 1514-1523.
[14]
R. Lopez-Andujar, S. Deusa, E. Montalva, et al., “Comparative Prospective Study of Two Liver Graft Preservation Solutions: University of Wisconsin and Celsior,” Liver Transplantation, Vol. 15, No. 12, 2009, pp. 1709-1717. doi:10.1002/lt.21945
[15]
U. Maggi, L. Caccamo, S. Gatti, et al., “Celsior Solution and Clinical Liver Transplantation,” Transplantation Proceedings, Vol. 32, No. 1, 2000, pp. 36-37.
doi:10.1016/S0041-1345(99)00866-0
[16]
J. C. Meneu Diaz, E. Vicente, J. Nuno, et al., “Prospective Comparative Study of the Efficacy of Celsior Solution for Preservation in Clinical Liver Transplant,” Transplantation Proceedings, Vol. 34, No. 1, 2002, p. 49.
[17]
P. Michel, R. Vial, C. Rodriguez and R. Ferrera, “A Comparative Study of the Most Widely Used Solutions for Cardiac Graft Preservation during Hypothermia,” The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation, Vol. 21, No. 9, 2002, pp. 1030-1039.
[18]
B. Nardo, P. Beltempo, R. Bertelli, et al., “Comparison of Celsior and University of Wisconsin Solutions in Cold Preservation of Liver from Octogenarian Donors,” Transplantation Proceedings, Vol. 36, No. 3, 2004, pp. 523-524.
[19]
P. Pedotti, M. Cardillo, P. Rigotti, et al., “A Comparative Prospective Study of Two Available Solutions for Kidney and Liver Preservation,” Transplantation, Vol. 77, No. 10, 2004, pp. 1540-1545.
doi:10.1097/01.TP.0000132278.00441.CF
[20]
A. Knuth, H. Gabbert, W. Dippold, et al., “Biliary Adenocarcinoma. Characterisation of Three New Human Tumor Cell Lines,” Journal of Hepatology, Vol. 1, No. 6, 1985, pp. 579-596. doi:10.1016/S0168-8278(85)80002-7
[21]
N. Akamatsu, Y. Sugawara and D. Hashimoto, “Biliary Reconstruction, Its Complications and Management of Biliary Complications after Adult Liver Transplantation: A Systematic Review of the Incidence, Risk Factors and Outcome,” Transplant International, Vol. 24, No. 4, 2011, pp. 379-392. doi:10.1111/j.1432-2277.2010.01202.x
[22]
M. Gastaca, “Biliary Complications after Orthotopic Liver Transplantation: A Review of Incidence and Risk Factors,” Transplantation Proceedings, Vol. 44, No. 6, 2012, pp. 1545-1549. doi:10.1016/j.transproceed.2012.05.008
[23]
M. Scotte, B. Dousset, Y. Calmus, et al., “The Influence of Cold Ischemia Time on Biliary Complications Following Liver Transplantation,” Journal of Hepatology, Vol. 21, No. 3, 1994, pp. 340-346.
doi:10.1016/S0168-8278(05)80311-3
[24]
M. L. DeOliveira, W. Jassem, R. Valente, et al., “Biliary Complications after Liver Transplantation Using Grafts from Donors after Cardiac Death: Results from a Matched Control Study in a Single Large Volume Center,” Annals of Surgery, Vol. 254, No. 5, 2011, pp. 716-722.
[25]
D. X. Cui, J. Q. Yin, W. X. Xu, et al., “Effect of Different Bile Duct Flush Solutions on Biliary Tract Preservation Injury of Donated Livers for Transplantation,” Transplantation Proceedings, Vol. 42, No. 5, 2010, pp. 1576-1581. doi:10.1016/j.transproceed.2009.12.057
[26]
L. Feng, N. Zhao, X. Yao, et al., “Histidine-Tryptophan-Ketoglutarate Solution vs. University of Wisconsin Solution for Liver Transplantation: A Systematic Review,” Liver Transplantation, Vol. 13, No. 8, 2007, pp. 1125-1136. doi:10.1002/lt.21208
[27]
J. Erhard, R. Lange, R. Scherer, et al., “Comparison of Histidine-Tryptophan-Ketoglutarate (HTK) Solution versus University of Wisconsin (UW) Solution for Organ Preservation in Human Liver Transplantation. A Prospective, Randomized Study,” Transplant International, Vol. 7, No. 3, 1994, pp. 177-181.
[28]
Z. A. Stewart, A. M. Cameron, A. L. Singer, R. A. Montgomery and D. L. Segev, “Histidine-Tryptophan-Ketoglutarate (HTK) Is Associated with Reduced Graft Survival in Deceased Donor Livers, Especially Those Donated after Cardiac Death,” American Journal of Transplantation, Vol. 9, No. 2, 2009, pp. 286-293.
doi:10.1111/j.1600-6143.2008.02478.x
[29]
G. Testa, M. Malago, S. Nadalin, et al., “Histidine-Tryptophan-Ketoglutarate versus University of Wisconsin Solution in Living Donor Liver Transplantation: Results of a Prospective Study,” Liver Transplantation, Vol. 9, No. 8, 2003, pp. 822-826. doi:10.1053/jlts.2003.50168
[30]
X. N. Feng, X. Xu and S. S. Zheng, “Current Status and Perspective of Liver Preservation Solutions,” Hepatobiliary and Pancreatic Diseases International, Vol. 5, No. 4, 2006, pp. 490-494.
[31]
H. Janssen, P. H. Janssen and C. E. Broelsch, “Value of Energy Substrates in HTK and UW to Protect Human Liver Endothelial Cells against Ischemia and Reperfusion Injury,” European Surgery Research, Vol. 36, No. 1, 2004, pp. 26-32. doi:10.1159/000075071
[32]
C. Moench and G. Otto, “Ischemic Type Biliary Lesions in Histidine-Tryptophan-Ketoglutarate (HTK) Preserved Liver Grafts,” International Journal of Artificial Organs, Vol. 29, No. 3, 2006, pp. 329-334.
[33]
C. J. O’Connor, R. G. Wallace, K. Iwamoto, T. Taguchi and J. Sunamoto, “Bile Salt Damage of Egg Phosphatidylcholine Liposomes,” Biochimica et Biophysica Acta, Vol. 817, No. 1, 1985, pp. 95-102.
[34]
D. Komichi, S. Tazuma, T. Nishioka, et al., “Unique Inhibition of Bile Salt-Induced Apoptosis by Lecithins and Cytoprotective Bile Salts in Immortalized Mouse cholangiocytes,” Digestive Diseases and Sciences, Vol. 48, No. 12, 2003, pp. 2315-2322.
doi:10.1023/B:DDAS.0000007869.67105.27
[35]
H. Hoekstra, R. J. Porte, Y. Tian, et al., “Bile Salt Toxicity Aggravates Cold Ischemic Injury of Bile Ducts after Liver Transplantation in Mdr2+/? Mice,” Hepatology, Vol. 43, 2006, pp. 1022-1031.%%
